and simplifies Royalty Pharma’s corporate structure. Second, the Board has approved a new $3 billion share repurchase program as part of the company’s evolving approach to returning capital to ...

“By combining Cosette’s strong portfolio with Mayne Pharma’s proven commercial expertise, the combined company will be well positioned to further invest in innovation, portfolio expansion ...